Helen Heslop
Director/Board Member at The Leukemia & Lymphoma Society, Inc.
Profile
Helen E.
Heslop is the founder of AlloVir, Inc. (founded in 2013) and Tikva Allocell Pte Ltd.
(founded in 2023).
Currently, Dr. Heslop holds the position of Director at The Leukemia & Lymphoma Society, Inc. since 2023.
Additionally, Dr. Heslop is a Director at the Center For Cell & Gene Therapy and Deputy Director at the Dan L.
Duncan Comprehensive Cancer Center.
Helen Heslop active positions
| Companies | Position | Start |
|---|---|---|
The Leukemia & Lymphoma Society, Inc.
 The Leukemia & Lymphoma Society, Inc. Miscellaneous Commercial ServicesCommercial Services The Leukemia & Lymphoma Society, Inc. operates as the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. The firm provides treatment for , lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. It identifies and funds the most promising blood cancer research projects and forges partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new therapies. The company is headquartered in Rye Brook, NY. | Director/Board Member | 2023-06-30 |
| Dan L. Duncan Comprehensive Cancer Center | Corporate Officer/Principal | - |
| Center For Cell & Gene Therapy | Director/Board Member | - |
Former positions of Helen Heslop
| Companies | Position | End |
|---|---|---|
| ALLOVIR, INC. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ALLOVIR, INC. | Health Technology |
| Private companies | 3 |
|---|---|
The Leukemia & Lymphoma Society, Inc.
The Leukemia & Lymphoma Society, Inc. Miscellaneous Commercial ServicesCommercial Services The Leukemia & Lymphoma Society, Inc. operates as the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. The firm provides treatment for , lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. It identifies and funds the most promising blood cancer research projects and forges partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new therapies. The company is headquartered in Rye Brook, NY. | Commercial Services |
| Center For Cell & Gene Therapy | |
| Dan L. Duncan Comprehensive Cancer Center |
- Stock Market
- Insiders
- Helen Heslop
